Maxim Group Sees Potential In Agile Therapeutics (AGRX); Hancock Jaffe (HJLI) In Focus; China Ceramics (CCCL) Stock Offering; FDA OKs Mirati's (MRTX) IND Application for KRAS G12C Inhibitor
Shares of Agile Therapeutics Inc. (Nasdaq:AGRX) climbed $0.043 (or +5.31%) to $0.853 on Thursday after analysts at Maxim Group initiated the company's stock with a "Buy" rating and a price target of $3.00, which indicates significant potential upside from current trading levels.
Agile Therapeutics focuses on the development and commercialization of prescription contraceptive products for women.
**
Hancock Jaffe Laboratories Inc. (Nasdaq:HJLI) shares surged $0.01 (or +0.53%) to $1.88 on Thursday's trading session.
HJLI specializes in developing and manufacturing bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has three product candidates: the porcine tissue based VenoValve, which is intended to be surgically implanted in the deep venous system of the leg to treat Chronic Venue Insufficiency; the CoreoGraft, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery, and a porcine tissue based heart valve, which based upon its relatively small size and increased output, is an ideal candidate for pediatric aortic/mitral valve replacement.
What You Need to Know About HJLI
**
Shares of China Ceramics Co., Ltd. (Nasdaq:CCCL) tumbled more than 20% in the extended session Thursday after the company reported a proposed registered public offering of its common stock and warrants.
China Ceramics is a leading manufacturer of ceramic tiles in China. Its ceramic tiles are used for exterior siding, interior flooring, and design in residential and commercial buildings.
**
Mirati Therapeutics, Inc. (Nasdaq:MRTX) said after the closing bell Thursday that the FDA has cleared its investigational new drug (IND) application for MRTX849, a small molecule inhibitor of KRAS G12C.
FDA clearance of the IND enables Mirati to initiate its planned Phase 1/2 clinical trial in patients with advanced solid tumors that harbor KRAS G12C mutations.
Mirati Therapeutics is a clinical-stage oncology company developing product candidates to address the genetic, epigenetic and immunological promoters of cancer.
****
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer